[REVISION HISTORY]

Prostate cancer detection and treatment advancements

Updated 6 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-19 21:08 UTC → 2026-09-28 22:30 UTC · added ~~removed~~

Medical research and clinical guidance regarding prostate cancer continue to focus on improving early detection and personalizing treatment strategies. Researchers at Moffitt Cancer Center and Oxford University have developed mathematical biomarkers, such as the Adaptive Therapy Score (AT Score) and Expected Time to Progression (eTTP), to assist in adaptive therapy. This approach uses data from routine prostate-specific antigen (PSA) blood tests to help physicians determine when to pause or restart treatment, aiming to slow the growth of drug-resistant cells. In observance of World Prostate Cancer Awareness Day, medical experts have reiterated the critical importance of early diagnosis. Specialists warn that the disease often progresses silently in its initial stages. Common symptoms that warrant attention include difficulty urinating, weak urine flow, frequent urination (particularly at night), and blood in the urine or semen. Dr. Przemysław Mitura has noted that urinary changes can sometimes be mistaken for benign enlargement. While routine PSA testing and examinations are generally recommended starting at age 50 for men without specific risk factors, those with a family history of prostate, breast, ovarian, or pancreatic cancer should begin at age 40 or 45. Recent international research from the US and UK has also highlighted a link between accelerated biological aging and increased cancer risk. In Turkey, where prostate cancer is the second most common cancer among men after lung cancer, medical experts are emphasizing similar screening precautions. Although Turkey lacks a national screening program, specialists note Experts emphasize that PSA blood tests cannot entirely replace physical rectal examinations, as certain conditions may not be detectable through blood tests or imaging alone. ~~Symptoms requiring attention also include back or flank pain.~~ In Turkey, where prostate cancer is the second most common cancer among men after lung cancer, specialists continue to recommend regular evaluations for men over 50 to improve survival rates through early intervention. Additionally, during the 2nd European Summit on Cancer Prevention and Control, discussions have emerged regarding the need for better coordination in cancer prevention, including the potential role of a regulated 'preventer' profession to navigate screening programs and patient follow-up.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.